Our source library

Sources & further reading

Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.

1. CoreAge Rx: current advertised treatments and pricesStandard GLP-1 prices use the publisher-supplied correction: semaglutide $79/month from; tirzepatide $129/month from. Other original service details retain their October 8 check date. · Checked October 8, 2026
2. CoreAge Rx Help Center: current product catalogProvider formulation and consultation information · Checked October 8, 2026
3. Ro: weight-loss careProvider care model and current medication menu · Checked October 8, 2026
4. Ro: membership and medication pricingSeparate charges, prepayment periods and dose-specific offers · Checked October 8, 2026
5. Hers: weight-loss membershipMembership fee and medicine costs are separate · Checked October 8, 2026
6. Hers: Wegovy pillCurrent product page and starting medication quote · Checked October 8, 2026
7. Hers: Zepbound KwikPenProduct format, membership requirement and cancellation explanation · Checked October 8, 2026
8. Mochi Health: current care modelProvider membership and care overview · Checked October 8, 2026
9. Mochi: compounded semaglutideStarting medication quote; dose-dependent; membership extra · Checked October 8, 2026
10. Mochi: compounded tirzepatideStarting medication quote; dose-dependent; membership extra · Checked October 8, 2026
11. LillyDirect: Zepbound formats and pricesManufacturer fulfillment and self-pay program terms · Checked October 8, 2026
12. Lilly: Zepbound savings termsFormat-specific prices, eligibility and refill-window conditions · Checked October 8, 2026
13. Zepbound prescribing informationManufacturer prescribing information, warnings and approved uses · Checked October 8, 2026
14. Wegovy prescribing informationManufacturer labeling; formulation-specific directions and safety information · Checked October 8, 2026
15. FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026
16. Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026
17. Lilly: complete SURMOUNT-5 results and trial designTrial sponsor report; treatment-regimen estimand and safety-comparison limitations · Checked October 8, 2026
18. OrderlyMeds: current program prices and inclusionsOfficial source; commercial claims are attributed to the provider. · Checked October 10, 2026
19. WeightWatchers: Med+ membership, medication access and outcome footnotesMembership excludes GLP-1 medication. Behavioral-program comparison is an internal, nonrandomized analysis of self-reported weights. · Checked October 10, 2026